



PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction of Information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/736,188 **INFORMATION DISCLOSURE** Filing Date December 15, 2003 STATEMENT BY APPLICANT Katherine Bowdish First Named Inventor 1643 Art Unit (Use as many sheets as necessary) Examiner Name **Bradley Duffy** 2 Attorney Docket Number ALEX-P03-060 Sheet 1 of

U.S. PATENT DOCUMENTS					
Examiner	Cite No.1	Document Number Publication Date		Name of Patentee or	Pages, Columns, Lines, Where
Initials*		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevar Figures Appear
	AA1	US-7,238,352	07/03/2007	Gorczynski et al.	
	AA2	US-6,955,811	10-18-2005	Gorczynski et al.	
	AA3	US-20050169870-A1	08-04-2005	Truitt et al.	
	AA4	US-20050129690-A1	06-16-2005	Bowdish et al.	

FOREIGN PATENT DOCUMENTS						
	Cita	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	
	ВЗ	WO-9428027	12-08-1994	Arch Dev Corp et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CI2	Caldas et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Molecular Immunology</i> , 39(15):941-952 (2003).	
	CJ2	Chien et al., Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," PNAS, 86(14):5532-5536 (1989).	
	CK2	Cochlovius et al., "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 X CD19 Tandem Diaboty, and CD29 Costimulation," <i>Cancer Research</i> , 60:4336-4341 (2000).	
	CL2	Ebert et al., Selective Immunosuppressive Action of a Factor Produced by Colon Cancer Cells," Cancer Research, 50:6158-6161 (1990).	
	CM2	Faisal et al., "Cell-surface Associated p43/Endothelial-monocyte-activating-polypeptide-II in Hepatocellular Carcinoma Cells Induces Apoptosis in T-lymphocytes," <i>Asian Journal of Surgery</i> , 30(1):13-22 (2007).	
	CN2	Ginaldi et al., "Levels of Expression of CD52 in Normal and Leukemic B and T Cells: Correlation with In Vivo Therapeutic Response to Campath-1H," Leukemia Research, 22(2):185-191 (1998).	
	CO2	Giusti et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>PNAS</i> , 84(9):2926-2930 (1987).	
	CP2	Hardy et al., "A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mode," PNAS, 94:5756-5760 (1997).	
	CQ2	Iwanuma et al., "Antitumor Immune Response of Human Peripheral Blood Lymphocytes Coengrafted with Tumor into Severe Combined Immunodeficient Mice," Cancer Research,	

Examiner	Date	
Signature	Considered	L

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/736,188 Application Number INFORMATION DISCLOSURE December 15, 2003 Filing Date STATEMENT BY APPLICANT Katherine Bowdish First Named Inventor 1643 Art Unit (Use as many sheets as necessary) **Bradley Duffy** Examiner Name ALEX-P03-060 2 Attorney Docket Number of 2 Sheet

S7:2937-2942(1997). CR2 Liu et al., "Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude of kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients," <i>Clinical Transplantation</i> , 18:518-524 (2004). CS2 Mariuzza et al., "The Structural Basis of Antigen-Antibody Recognition," <i>Ann. Rev. Biophys. Chem.</i> , 16:139-159 (1987). CT2 Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia," <i>Proceedings</i> , Fifty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunoodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 28(6):650 (2006). CB3 Kretz-Rommel, A., et al., "The Immune Evasion by CD200: New Ap			
graft on the magnitude of kinetics of Epstein-Barr virus load in the perpheral blood of bone marrow transplant recipients," <i>Clinical Transplantation</i> , 18:518-524 (2004). CS2 Mariuzza et al., "The Structural Basis of Antigen-Antibody Recognition," <i>Ann. Rev. Biophys. Chem.</i> , 16:139-159 (1987). Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia," <i>Proceedings</i> , Fifty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). Kretz-Rommel, A., et al., "Cl200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CB3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Responses,"		57:2937-2942(1997).	
CS2 Mariuzza et al., "The Structural Basis of Antigen-Antibody Recognition," Ann. Rev. Biophys. Criem., 16:139-159 (1987). CT2 Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia," Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," J. Exp. Med., 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," PNAS, 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," Hybridoma, 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," Cancer Research, 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Toel/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CB3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia, "J. Immunother., 28(6):650 (2005). CC3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell	CI	graft on the magnitude of kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow	
 √ 16:139-159 (1987). C†2 Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia," <i>Proceedings</i>, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CUZ Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i>, 204:1-9 (2004). CVZ Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i>, 79:1979-1983 (1982). CWZ Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i>, 18(1):47-55 (1999). CXZ Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i>, 65(23):10646-10650 (2005). CYZ Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i>, 57:1335-1343 (1997). CZZ Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i>, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i>, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Toell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CB3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia, "J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The		transplant recipients, Clinical Process of Antigen-Antibody Recognition " Ann. Rev. Biophys. Chem.	
C†2 Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia," <i>Proceedings</i> , Fitty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Jeukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2	C	Mariuzza et al., The Structural basis of Artiger-Artibody Recognition,	
Iymphocyctic leukemia," <i>Proceedings</i> , Fifty-Ninth Annual Meeting of the Japanese Cancer Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kreitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CB3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):546 (2004).		to the stand from D obronic	
Association, page 583, #3788 (September 1, 2000). CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):546 (2004).	C	Mori et al., "Establishment of a new anti-caricer drugs-lesistant cell line derived nem of the Jananese Cancer	1
CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004). CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).		lymphocyctic leukemia, "Proceedings, Flity-Nillium Allituda Weeting of the Sapariess Salies"	V
CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," PNAS, 79.1979-1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," Hybridoma, 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," Cancer Research, 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).		Association, page 583, #3/88 (September 1, 2000).	
Type 1983 (1982). CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):546 (2004).	C	U2 Riley, "Melanoma and the Problem Malignancy," J. Exp. Med., 204:1-9 (2004).	
CW2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronallymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	С	V2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," PNAS, 79:1979-	
Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):4/-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).		1983 (1982).	
Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):4/-55 (1999). CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	C	W2 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a	
CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," Cancer Research, 65(23):10646-10650 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	1 1	Human-PBL-SCID/RG Mouse Model." Hybridoma, 18(1):47-55 (1999).	
Receptor 4 by Transducible Anticancer Peptides," Cancer Research, 65(23):1046-1050 (2005). CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).		V2 Spyder et al. "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine	
CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic 1 Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	"	Receptor 4 by Transducible Anticancer Peptides." Cancer Research, 65(23):10646-10650 (2005).	
Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	1	V2 Tanaka et al. "The Anti-Human Tumor Effect and Generation of Human Cytotoxic I Cells in SCID	
Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997). CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens, 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).		Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene	
CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	1	Using Adenovirus Vector," Cancer Research, 57:1335-1343 (1997).	
human alloreaction in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005). CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	1	72 Thomsen et al. "Reconstitution of a human immune system in immunodeficient mice: models of	
CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004).	1	human alloreaction in vivo " Tissue Antigens, 66:73-82 (2005).	
glycoprotein is conserved in humans," Immunology, 102:173-179 (2001). CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		A2 Wight of al. "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2)	
CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, 13:98-104 (1999). CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	1	AS Whigh et al., The undeal distribution of the property of th	
CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	I————	grycopotein s conserved in namana, mineracy, process, and the served in namana, mineracy, process, and the serv	
New Approaches to Cancer Immunotherapy," J. Immunother., 29(6):666 (2006). CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		B3 Knetz, C., et al., minimum of resing on Timor Cells Suppresses Anti-Tumor Immunity:	
CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	1	Kretz-Rommer, A., et al., CD200 Expression of Tuffield College (2006).	
Chronic Lymphocytic Leukemia," J. Immunother., 28(6):650 (2005). CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		New Approaches to Cancer Influence Large by C. Million March 2019, 2019, 1919	
CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	1 10	Kretz-Rommel, A., et al., "Immune Evasion by Cuzou." New Approaches to Talgotto Williams	
B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		Chronic Lymphocytic Leukemia, J. Immunotner., 20(0).000 (2003).	
Response," J. Immunother., 27(6):S46 (2004). CE3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	(E3 Kretz-Rommel, A., et al., "The immuno-Regulatory Polici Days Regulating the TH1 Immuno	
CF3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the 181 infinitine	
CF3 McWhirter J.R. et al., "Antibodies selected from combinatorial libraries block a tumor antigen that		Response," J. Immunother., 27(6):S46 (2004).	
plays a key role in immunomodulation," PNAS, 103(4):1041-1046 (2006).		F3. McWhirter J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that	
	1	plays a key role in immunomodulation," PNAS, 103(4):1041-1046 (2006).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	•	Date Considered	1
Signature		Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.